Looking Back, Looking Forward: Penn’s CAR-T Program Continues Path of Progress

The field of CAR T-cell therapy—and the number of lives saved by this personalized form of cellular therapy—has grown exponentially since the FDA approved the first such therapy in 2017, based on research led by Carl June, MD, the Richard W. Vague Professor in Immunotherapy. In this interview, Don L. Siegel, MD, PhD, a professor of Pathology and Laboratory Medicine and director of the Clinical Cell and Vaccine Production Facility, shared how Penn Medicine continues to lead the way in CAR T-cell therapy research.